跳到正文
ECA GMP News·AI 评分54

Swissmedic 发布医用大麻信息表 2.0 版并新增附录 3 常见问题

New Information Sheet regarding Cannabis for Medical Purposes

AI 导读

Swissmedic 发布了医用大麻信息表 2.0 版,新增附录 3 常见问题,用于说明医用大麻何时属于原料药、按配方制剂或成品药。附录 3 指出医用大麻可为原料药、非即用型中间产品或即用型成品药,按配方配制的药品不得交易,也不得进出口。原料药进出口仅限持有附表 A 所列管制物质经营许可并取得 Swissmedic 进出口许可的企业。

正文 · 原文

The Swissmedic recently published an updated Version 2.0 of the Information Sheet on Cannabis for Medical Purposes (Merkblatt Cannabis für medizinische Zwecke). It now includes a new Appendix 3 - FAQ on Cannabis for Medical Purposes, providing clarifications (among others) on when Cannabis is an API (Active Pharmaceutical Ingredient), when it is a preparation according to a Formula Magistralis, and when it is a Medicinal Product.Restrictions and Authorisation Requirements (Import/Export & Trade)According to the new Annex 3, Cannabis for Medical Purposes can be an API, a non-ready-to-use intermediate product, or a ready-to-use medicinal product. Trading in medicinal products prepared according to a formula magistralis is not permitted. Moreover, the import/export of medicinal products prepared according to a formula magistralis is not permitted. The import/export of APIs is permitted only for companies holding an operating licence to handle controlled substances listed in Schedule A, and only after obtaining a Swissmedic import or export permit.More informtion is available on the Swissmedic website "Cannabis for medical Purposes".

来源:ECA GMP News · gmp-compliance.org